{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:49:10Z","timestamp":1774435750170,"version":"3.50.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009614","name":"University of Rhode Island","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009614","id-type":"DOI","asserted-by":"publisher"}]},{"name":"College of Pharmacy Healthcare Research Operating Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A minority of patients with opioid use disorder are treated for hepatitis C virus infection (HCV). While colocated HCV and opioid agonist therapy (OAT) along with harm reduction can facilitate prevention and cascade to cure, there are few real-world examples of such embedded care models in the United States in the direct-acting antiviral (DAA) era.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective chart review to determine sustained virologic response (SVR) and reinfection rates during the first 5-year period of DAA availability among individuals tested and treated on-site at Rhode Island\u2019s only nonprofit methadone maintenance program.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 275 who initiated DAAs, the mean age (range) was 43 (22\u201371) years, 34.5% were female, 57.5% had genotype 1a, 23.3% had cirrhosis, and 92% were Medicaid recipients. SVR was 85.0% (232\/273), while modified intent-to-treat SVR was 93.2% (232\/249); 17 patients did not achieve SVR, 2 awaited SVR 12 weeks post-end-of-treatment, and 24 were lost to follow-up. Thirty reinfections were identified over 375.5 person-years of follow-up (rate, 7.99\/100 person-years). The median time to first reinfection (interquartile range) was 128 (85.25\u2013202.5) days. Before July 1, 2018, 72 patients accessed DAAs over 3.7 years; after Medicaid DAA restrictions were lifted, 109 patients accessed DAAs over 1.3 years. The Prior Authorization (PA) process requires many steps, differing across 11 RI insurers, taking 45\u2013120 minutes per patient.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>DAA treatment was effective among a marginalized population in an urban colocated OAT\/HCV program. Removing DAA restrictions facilitates treatment initiation. The PA process remains a modifiable barrier to expanding capacity in the United States.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaa310","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T04:05:07Z","timestamp":1602561907000},"source":"Crossref","is-referenced-by-count":13,"title":["Optimizing Hepatitis C Virus (HCV) Treatment in a US Colocated HCV\/Opioid Agonist Therapy Program"],"prefix":"10.1093","volume":"7","author":[{"given":"Jackie","family":"Habchi","sequence":"first","affiliation":[{"name":"CODAC Behavioral Healthcare, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurielle M","family":"Thomas","sequence":"additional","affiliation":[{"name":"University of Rhode Island, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Sprecht-Walsh","sequence":"additional","affiliation":[{"name":"CODAC Behavioral Healthcare, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elenita","family":"Arias","sequence":"additional","affiliation":[{"name":"CODAC Behavioral Healthcare, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Bratberg","sequence":"additional","affiliation":[{"name":"University of Rhode Island, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Hurley","sequence":"additional","affiliation":[{"name":"CODAC Behavioral Healthcare, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Hart","sequence":"additional","affiliation":[{"name":"CODAC Behavioral Healthcare, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0472-8125","authenticated-orcid":false,"given":"Lynn E","family":"Taylor","sequence":"additional","affiliation":[{"name":"CODAC Behavioral Healthcare and University of Rhode Island, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"2020101623344496200_CIT0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","article-title":"CDC recommendations for hepatitis C screening among adults - United States, 2020","volume":"69","author":"Schillie","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2020101623344496200_CIT0002","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S2468-1253(18)30304-2","article-title":"Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis","volume":"3","author":"Hajarizadeh","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020101623344496200_CIT0003","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1093\/cid\/ciz696","article-title":"Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis","volume":"70","author":"Graf","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2020101623344496200_CIT0004","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2020101623344496200_CIT0005","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"2020101623344496200_CIT0006","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/cid\/ciz693","article-title":"Low hepatitis C reinfection following direct-acting antiviral therapy among people who inject drugs on opioid agonist therapy","volume":"70","author":"Akiyama","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2020101623344496200_CIT0007","doi-asserted-by":"crossref","first-page":"e12411","DOI":"10.5812\/hepatmon.12411","article-title":"Effectiveness of methadone maintenance treatment in prevention of hepatitis C virus transmission among injecting drug users","volume":"13","author":"Alavian","year":"2013","journal-title":"Hepat Mon"},{"key":"2020101623344496200_CIT0008","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1001\/jamainternmed.2014.5416","article-title":"Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users","volume":"174","author":"Tsui","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2020101623344496200_CIT0009","doi-asserted-by":"crossref","first-page":"e1208","DOI":"10.1016\/S2214-109X(17)30373-X","article-title":"Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review","volume":"5","author":"Larney","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2020101623344496200_CIT0010","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy","volume":"57","author":"Martin","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020101623344496200_CIT0011","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/add.14012","article-title":"Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane review and meta-analysis","volume":"113","author":"Platt","year":"2018","journal-title":"Addiction"},{"key":"2020101623344496200_CIT0012","author":"National Institute on Drug Abuse"},{"key":"2020101623344496200_CIT0013","doi-asserted-by":"crossref","first-page":"e1002963","DOI":"10.1371\/journal.pmed.1002963","article-title":"Defining a recovery-oriented cascade of care for opioid use disorder: a community-driven, statewide cross-sectional assessment","volume":"16","author":"Yedinak","year":"2019","journal-title":"PLoS Med"},{"key":"2020101623344496200_CIT0014","first-page":"19","article-title":"Estimating the true prevalence of hepatitis C in Rhode Island","volume":"97","author":"Kinnard","year":"2014","journal-title":"R I Med J"},{"key":"2020101623344496200_CIT0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMp1803982","article-title":"Methadone in primary care - one small step for Congress, one giant leap for addiction treatment","volume":"379","author":"Samet","year":"2018","journal-title":"N Engl J Med"},{"key":"2020101623344496200_CIT0016","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Ann Intern Med"},{"key":"2020101623344496200_CIT0017","author":"National AIDS Treatment Advocacy Project"},{"key":"2020101623344496200_CIT0018","author":"American Association for the Study of Liver Diseases-Infectious Disease Society of America"},{"key":"2020101623344496200_CIT0019","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.drugpo.2019.03.017","article-title":"Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston","volume":"72","author":"Beiser","year":"2019","journal-title":"Int J Drug Policy"},{"key":"2020101623344496200_CIT0020","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/jvh.12666","article-title":"HCV reinfection incidence among individuals treated for recent infection","volume":"24","author":"Martinello","year":"2017","journal-title":"J Viral Hepatitis"},{"key":"2020101623344496200_CIT0021","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa105","article-title":"Concurrent initiation of hepatitis C and opioid use disorder treatment in people who inject drugs","author":"Rosenthal","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2020101623344496200_CIT0022","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsat.2016.12.014","article-title":"Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program","volume":"75","author":"Butner","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"2020101623344496200_CIT0023","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drugpo.2018.06.019","article-title":"Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada","volume":"59","author":"Nouch","year":"2018","journal-title":"Int J Drug Policy"},{"key":"2020101623344496200_CIT0024","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jsat.2019.01.021","article-title":"Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore","volume":"100","author":"Falade-Nwulia","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"2020101623344496200_CIT0025","author":"Substance Abuse and Mental Health Service Administration"},{"key":"2020101623344496200_CIT0026","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","article-title":"Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis","volume":"72","author":"Hajarizadeh","year":"2020","journal-title":"J Hepatol"},{"key":"2020101623344496200_CIT0027","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/hep.24374","article-title":"Distributive justice and the arrival of direct-acting antivirals: who should be first in line?","volume":"53","author":"Aronsohn","year":"2011","journal-title":"Hepatology"},{"key":"2020101623344496200_CIT0028","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.idc.2018.02.011","article-title":"Hepatitis C care in the Department of Veterans Affairs: building a foundation for success","volume":"32","author":"Belperio","year":"2018","journal-title":"Infect Dis Clin North Am"},{"key":"2020101623344496200_CIT0029","author":"Substance Abuse and Mental Health Services Administration","year":"2018"},{"key":"2020101623344496200_CIT0030","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/cid\/ciy899","article-title":"Integrated, co-located, telemedicine-based treatment approaches for hepatitis C virus management in opioid use disorder patients on methadone","volume":"69","author":"Talal","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/10\/ofaa310\/33913432\/ofaa310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/10\/ofaa310\/33913432\/ofaa310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T03:35:05Z","timestamp":1602905705000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa310\/5921596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa310","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,10,1]]},"article-number":"ofaa310"}}